Drug intelligence / Profile preview

[18F]myo-4

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

[18F]myo-4 is one of eight new [18F]fluoro-inositol-based radiotracers developed for Positron Emission Tomography (PET) imaging. It is a myo-inositol configured radiotracer equipped with a propyl linker bearing fluorine-18. These radiotracers were synthesized in both acetylated or hydroxylated forms to modulate lipophilicity. Automated radiosynthesis was performed on the AllInOne module. Preliminary in vivo preclinical evaluation was conducted in a breast tumour-bearing mouse model to assess its potential as an imaging agent for breast cancer.

Beyond the preview

Go deeper on [18F]myo-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]myo-4.

Explore the full profile